Praxis Precision MedicinesPRAX
PRAX
About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Employees: 82
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
42% more capital invested
Capital invested by funds: $770M [Q2] → $1.09B (+$321M) [Q3]
20% more call options, than puts
Call options by funds: $24M | Put options by funds: $20M
18% more funds holding
Funds holding: 113 [Q2] → 133 (+20) [Q3]
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]
2.55% less ownership
Funds ownership: 108.82% [Q2] → 106.27% (-2.55%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$120
44%
upside
Avg. target
$149
78%
upside
High target
$175
110%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Joon Lee 53% 1-year accuracy 23 / 43 met price target | 110%upside $175 | Buy Maintained | 21 Jan 2025 |
HC Wainwright & Co. Douglas Tsao 37% 1-year accuracy 65 / 175 met price target | 44%upside $120 | Buy Reiterated | 12 Dec 2024 |
Needham Ami Fadia 51% 1-year accuracy 84 / 165 met price target | 81%upside $151 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Based on 3 articles about PRAX published over the past 30 days
Neutral
GlobeNewsWire
7 hours ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 3, 2025, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 4,050 shares of its common stock and restricted stock unit awards covering an aggregate of 3,038 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 day ago
Praxis Precision Medicines to Present at Two February Investor Conferences
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences:
Neutral
GlobeNewsWire
3 weeks ago
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028
Neutral
GlobeNewsWire
1 month ago
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025 BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for relutrigine in Dravet syndrome. “We are thrilled to have been granted rare pediatric disease designation for relutrigine in Dravet syndrome.
Neutral
Business Wire
2 months ago
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.
Neutral
GlobeNewsWire
2 months ago
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
Neutral
GlobeNewsWire
2 months ago
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.
Neutral
Seeking Alpha
2 months ago
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO Tim Kelly - CFO Conference Call Participants Ritu Baral - TD Cowen Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Douglas Tsao - H.C. Wainwright Kambiz Yazdi - Jefferies Ami Fadia - Needham Joel Beatty - Baird Laura Chico - Wedbush Securities Operator Good day and thank you for standing by.
Negative
Zacks Investment Research
2 months ago
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025
Charts implemented using Lightweight Charts™